IONIQ Sciences / News  / IONIQ Presents Lung Cancer Trial Results at ATS 2022

IONIQ Presents Lung Cancer Trial Results at ATS 2022

Salt Lake City, UT, May 19, 2022 – IONIQ Sciences is proud of our team members who presented our latest lung cancer clinical trial results in a poster today at the American Thoracic Society meeting in San Francisco, CA. This was a great honor to highlight our growing bioimpedance clinical evidence that continues to demonstrate the possibility of a non-invasive, low-cost, early-stage lung cancer diagnosis.

Furthermore, the clinical evidence across different cancer types continues to prove that early detection saves money and lives. When cancer can be diagnosed in the earliest and most treatable stages, survival rates are ~90%. Early detection matters most and IONIQ Sciences is focused on making it a reality with our non-invasive bioimpedance technology. Watch us modernize early-stage cancer detection. 


About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. For more information visit:


About BioHive
IONIQ Sciences is proud to be a key supporter and member of the newly formed BioHive, a collective representing the life science and healthcare innovation ecosystem. By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America and their innovations are improving the lives of millions of patients. To learn more, visit:


IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103